Literature DB >> 21499129

Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?

Mikael Sundin1, Pádraig D'arcy, C Christian Johansson, A John Barrett, Helena Lönnies, Berit Sundberg, Silvia Nava, Rolf Kiessling, Dimitrios Mougiakakos, Katarina Le Blanc.   

Abstract

Multipotent mesenchymal stromal cells (MSCs) have immunosuppressive capacity but the exact mechanism by which they suppress proliferation of T lymphocytes is not fully understood. Recently, the characteristics and function of regulatory T lymphocytes (Tregs) have become better defined. Tregs and MSCs have immunosuppressive features in common. Here, we looked for a common basis for immunosuppression in these distinct cell types. Forkhead box P3 (FoxP3) and CD39 expression in MSCs was measured by flow cytometry and real-time quantitative polymerase chain reaction. The importance of FoxP3 in MSC-mediated immunosuppression was investigated by siRNA technology and mixed lymphocyte culture (MLC). The effect of 5-azacytidine and other immunosuppressive drugs on FoxP3 expression and immunosuppression by MSCs was explored by flow cytometry, MLC, and real-time quantitative polymerase chain reaction. MSCs express FoxP3 at variable levels, but they do not express CD39. FoxP3 MSCs suppress MLC to a greater extent than cells with lower FoxP3 expression. However, FoxP3-decreased MSCs were found to retain their immunosuppressive properties. 5-azacytitine had no effect on FoxP3 expression or MLC suppression by MSCs. However, immunosuppressive drugs led to increased FoxP3 levels and MLC inhibition in FoxP3 MSCs. This is the first demonstration of FoxP3 expression by MSCs. Although MSCs share several features with Tregs, and FoxP3 MSCs tend to be more immunosuppressive, MSCs do not require functional FoxP3 for their immunosuppressive activity. The increased MSC-mediated suppression of immune responses by immunosuppressive drugs deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21499129      PMCID: PMC4157637          DOI: 10.1097/CJI.0b013e318217007c

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  41 in total

1.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Authors:  Katarina Le Blanc; Ida Rasmusson; Berit Sundberg; Cecilia Götherström; Moustapha Hassan; Mehmet Uzunel; Olle Ringdén
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

Review 2.  Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression.

Authors:  Bin Li; Sandra J Saouaf; Arabinda Samanta; Yuan Shen; Wayne W Hancock; Mark I Greene
Journal:  Curr Opin Immunol       Date:  2007-08-20       Impact factor: 7.486

Review 3.  Regulatory T cells as therapeutic cells.

Authors:  Pervinder Sagoo; Giovanna Lombardi; Robert I Lechler
Journal:  Curr Opin Organ Transplant       Date:  2008-12       Impact factor: 2.640

4.  Induction of DNA synthesis in human lymphocytes: interaction between non-specific mitogens and antigens.

Authors:  G Möller
Journal:  Immunology       Date:  1970-10       Impact factor: 7.397

5.  Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans.

Authors:  Torsten Böhler; Jochen Nolting; Nassim Kamar; Purevtseren Gurragchaa; Kathrin Reisener; Petra Glander; Hans-H Neumayer; Klemens Budde; Jochen Klupp
Journal:  Ther Drug Monit       Date:  2007-02       Impact factor: 3.681

6.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

7.  Effects of ciclosporin A, tacrolimus and sirolimus on cytokine production in neonatal immune cells.

Authors:  Alexander Puzik; Christian Schultz; Peter Iblher; Michael Müller-Steinhardt; Christoph Härtel
Journal:  Acta Paediatr       Date:  2007-10       Impact factor: 2.299

8.  Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation.

Authors:  Jorge Vela-Ojeda; Laura Montiel-Cervantes; Perla Granados-Lara; Elba Reyes-Maldonado; Ethel García-Latorre; Jaime Garcia-Chavez; Abraham Majluf-Cruz; Hector Mayani; Jose R Borbolla-Escoboza; Miriam García-Ruiz Esparza
Journal:  Stem Cells Dev       Date:  2010-03       Impact factor: 3.272

9.  Mesenchymal stem cells avoid allogeneic rejection.

Authors:  Jennifer M Ryan; Frank P Barry; J Mary Murphy; Bernard P Mahon
Journal:  J Inflamm (Lond)       Date:  2005-07-26       Impact factor: 4.981

10.  Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects.

Authors:  Luis A Ortiz; Frederica Gambelli; Christine McBride; Dina Gaupp; Melody Baddoo; Naftali Kaminski; Donald G Phinney
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-18       Impact factor: 12.779

View more
  10 in total

Review 1.  Are stem cells a potential therapeutic tool in coeliac disease?

Authors:  Rachele Ciccocioppo; Giuseppina Cristina Cangemi; Emanuela Anna Roselli; Peter Kruzliak
Journal:  Cell Mol Life Sci       Date:  2014-12-16       Impact factor: 9.261

2.  Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming.

Authors:  Mehdi Najar; Gordana Raicevic; Hussein Fayyad-Kazan; Hussein Fayyad Kazan; Cécile De Bruyn; Dominique Bron; Michel Toungouz; Laurence Lagneaux
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

3.  Regulatory T-cells within bone marrow-derived stem cells actively confer immunomodulatory and neuroprotective effects against stroke.

Authors:  Elliot G Neal; Sandra A Acosta; Yuji Kaneko; Xunming Ji; Cesario V Borlongan
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-23       Impact factor: 6.200

4.  Gene and cell therapy based treatment strategies for inflammatory bowel diseases.

Authors:  Sander van der Marel; Anna Majowicz; Sander van Deventer; Harald Petry; Daniel W Hommes; Valerie Ferreira
Journal:  World J Gastrointest Pathophysiol       Date:  2011-12-15

Review 5.  Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression.

Authors:  Martha de Oliveira Bravo; Juliana Lott Carvalho; Felipe Saldanha-Araujo
Journal:  Purinergic Signal       Date:  2016-08-25       Impact factor: 3.765

6.  Obesity Affects the Proliferative Potential of Equine Endometrial Progenitor Cells and Modulates Their Molecular Phenotype Associated with Mitochondrial Metabolism.

Authors:  Agnieszka Smieszek; Klaudia Marcinkowska; Ariadna Pielok; Mateusz Sikora; Lukas Valihrach; Elaine Carnevale; Krzysztof Marycz
Journal:  Cells       Date:  2022-04-24       Impact factor: 7.666

7.  Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages.

Authors:  Marilena Ciciarello; Roberta Zini; Lara Rossi; Valentina Salvestrini; Davide Ferrari; Rossella Manfredini; Roberto M Lemoli
Journal:  Stem Cells Dev       Date:  2012-12-21       Impact factor: 3.272

8.  Biologic and immunomodulatory properties of mesenchymal stromal cells derived from human pancreatic islets.

Authors:  Jaehyup Kim; Melissa J Breunig; Leah E Escalante; Neehar Bhatia; Ryan A Denu; Bridget A Dollar; Andrew P Stein; Summer E Hanson; Nadia Naderi; James Radek; Dermot Haughy; Debra D Bloom; Fariba M Assadi-Porter; Peiman Hematti
Journal:  Cytotherapy       Date:  2012-05-09       Impact factor: 5.414

9.  Adipose stromal vascular fraction attenuates TH1 cell-mediated pathology in a model of multiple sclerosis.

Authors:  Annie C Bowles; Rachel M Wise; Brittany Y Gerstein; Robert C Thomas; Roberto Ogelman; Regan C Manayan; Bruce A Bunnell
Journal:  J Neuroinflammation       Date:  2018-03-13       Impact factor: 8.322

10.  Immunomodulatory Properties of Adipose-Derived Stem Cells Treated with 5-Azacytydine and Resveratrol on Peripheral Blood Mononuclear Cells and Macrophages in Metabolic Syndrome Animals.

Authors:  Katarzyna Kornicka; Agnieszka Śmieszek; Agnieszka Sławomira Węgrzyn; Michael Röcken; Krzysztof Marycz
Journal:  J Clin Med       Date:  2018-10-24       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.